StockData
Wave Life Sciences, Inc. logo

Wave Life Sciences, Inc. (WVE) company profile

WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)

Close on Nov 17, 2026Market cap $560.13MP/E –Yield –

About Wave Life Sciences

Pharmaceutical Preparations, SIC 2834

Wave Life Sciences is a clinical-stage biotechnology company developing ribonucleic acid (RNA) medicines to treat rare and prevalent human disorders. Utilizing its proprietary PRISM platform, the company designs stereopure oligonucleotides across modalities including RNA interference, RNA editing, antisense silencing, and splicing. Its therapeutic pipeline focuses on clinical candidates for obesity, alpha-1 antitrypsin deficiency, and PNPLA3-related liver disease, alongside clinical programs targeting Duchenne muscular dystrophy and Huntington’s disease. Wave collaborates with strategic pharmaceutical partners, including GSK, to advance preclinical discovery programs and develop therapeutics addressing both hepatic and extra-hepatic targets.

The company operates an internal manufacturing facility in Lexington, Massachusetts, capable of producing stereopure oligonucleotides from discovery scale to potential commercial volumes. It maintains research and clinical operations primarily across the United States and Europe, conducting multinational clinical trials across various site networks. Waves conducts its corporate, development, and manufacturing activities out of its primary facilities in Massachusetts.

Summary of the business section of Wave Life Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Wave Life Sciences, Inc.
Headquarters
Cambridge, MA
Address
733 Concord Avenue 02138
Phone
(617) 949-2900
Employees
317, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, MA

Stock & identifiers

Ticker
WVE
Exchange
Nasdaq
IPO date
Nov 11, 2015
Shares outstanding
197M, Oct 21, 2026
Public float
$851.01M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1631574
CUSIP
94352A104
ISIN
US94352A1043
FIGI
BBG0248CHKR2
Share class FIGI
BBG0248CHL36
LEI
54930070006GPKFYZ813
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul BolnoPresident and CEO, Director275,520
Erik IngelssonChief Scientific Officer87,864
Christopher I. WrightChief Medical Officer45,625
Chris FrancisSee Remarks61,867
Chandra VargeeseSee Remarks408,246
Kyle MoranChief Financial Officer134,385
Heidi L. WagnerDirector55,630
Aik Na TanDirector35,668
Adrian RawcliffeDirector10,700
Gregory L. VerdineDirector275,917
Mark CorriganDirector39,515
Capital Healthcare Fund LP RADirector28,815
Rajeev M. ShahDirector–
Peter KolchinskyDirector19,202,009
Ra Capital Management, L.P.Director39,515
Christian O. HenryDirector23,400
Ken TakanashiDirector9,637,187

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$12.28M$18.59M$3.21M$216$66
FY2024$4.27M$17.39M$1.79M$157$37
FY2023$3.87M$2.22M$1.74M$64$43
FY2022$2.67M$6.08M$1.19M$89$48
FY2021$3.89M$1.27M$1.53M$40$77

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Paul B. Bolno, M.D., MBA
President and Chief Executive Officer
$700.00K$1.42M$9.51M$614.25K$36.83K$12.28M+187%
Kyle Moran, CFA
Chief Financial Officer
$520.10K$493.08K$2.40M$331.76K$12.82K$3.75M+96%
Chandra Vargeese, Ph.D.
Chief Technology Officer, Head of Platform Discovery Sciences
$502.20K$434.38K$2.13M$320.34K$14.06K$3.40M+80%
Christopher Francis, Ph.D.
Chief Strategy Officer
$451.40K$293.50K$1.44M$274.23K$11.31K$2.47M+57%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 317 employees, all of whom were full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 10, 2026DeregistrationTermination of SEC registration (Form 15)
Jul 30, 2026Name changeName changed from WAVE Life Sciences Ltd. to Wave Life Sciences, Inc.
Nov 9, 2015ListingRegistration of securities on an exchange (Form 8-A)
Nov 2, 2015Name changeName changed from Wave Life Sciences Pte Ltd to Wave Life Sciences Ltd.

See a number that looks wrong?